证券代码：300238 证券简称：冠昊生物 公告编号：2025-041 冠昊生物科技股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 现场会议召开时间：2025 年 6 月 23 日下午 15:00 冠昊生物科技股份有限公司(以下简称"公司")第六届董事会第十四次会议 审议通过，决定于 2025 年 6 月 23 日召开 2025 年第二次临时股东大会，现将会 议相关事项通知如下： 一、召开会议的基本情况 （一）股东大会届次：2025 年第二次临时股东大会 （二）会议召集人：公司董事会 （三）会议召开的合法、合规性：经公司第六届董事会第十四次会议审议通 过，决定召开 2025 年第二次临时股东大会，召集程序符合有关法律法规、规范 性文件和《公司章程》的有关规定。 （四）会议召开日期和时间： 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为：2025 年 6 月 23 日上午 9:15—9:25，9:30—11:30 和下午 13:00—15:00；通过深圳证券 交易所互联网投票系统进行投 ...

证券代码：300238 证券简称：冠昊生物 公告编号：2025-038 冠昊生物科技股份有限公司 第六届监事会第十一次会议决议公告 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 1、冠昊生物科技股份有限公司(以下简称"公司")第六届监事会第十一次 会议，会议通知已于 2025 年 6 月 3 日以专人送达、邮件等方式送达全体监事。 2、本次会议于 2025 年 6 月 6 日下午 15:00 在公司会议室采取现场会议和通 讯会议相结合的方式召开。 3、本次会议应出席监事 3 名，实际出席会议监事 3 名。其中，监事田丹女 士、赵剑翼先生以通讯方式出席会议。 4、本次会议由公司监事会主席田丹女士召集并主持。 5、本次会议的召集和召开符合《公司法》《公司章程》和《监事会议事规 则》的有关规定。 二、监事会会议审议情况 会议采取记名投票的方式进行表决，经与会的监事充分讨论与审议，会议形 成以下决议： （一）审议通过《关于修订<公司章程>及其附件的议案》 监事会经审核认为：本次对现行《公司章程》及其附件（《股东会议事规 则》和《董事会议事规 ...

一、董事会会议召开情况 1、冠昊生物科技股份有限公司(以下简称"公司")第六届董事会第十四次 会议，会议通知已于 2025 年 6 月 3 日以专人送达、邮件等方式送达全体董事。 2、本次会议于 2025 年 6 月 6 日下午 14:00 在公司会议室采取现场会议和通 讯会议相结合的方式召开。 3、本次会议应出席董事 5 名，实际出席会议董事 5 名。其中，董事孙峰女 士、独立董事韩俊梅女士、邓超先生以通讯方式出席会议。 证券代码：300238 证券简称：冠昊生物 公告编号：2025-037 冠昊生物科技股份有限公司 第六届董事会第十四次会议决议公告 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 4、本次会议由公司董事长张永明先生召集并主持，公司监事、高级管理人 员列席了会议。 二、董事会会议审议情况 会议采取记名投票的方式进行表决，经与会董事的认真审议与表决，形成如 下决议： （一） 审议通过《关于修订<公司章程>及其附件的议案》 根据《公司法》《上市公司章程指引》《深圳证券交易所创业板股票上市规 则》《深圳证券交易所上市公司自律监管指引第 2 号—— ...

Group 1 - The core business of the company focuses on developing new products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure [2] - The main products include biological dura (spinal) membrane patches, B-type dura (spinal) membrane patches, thoracic repair membranes, sterile biological dressings, and other specialized medical materials [2] - The company has achieved a revenue of 94.8 million yuan in Q1 2025, representing a year-on-year growth of 3.67%, with a net profit of 14.9 million yuan, also up by 3.30%, and a gross profit margin of 77.05% [2] Group 2 - As of June 5, the company's stock closed at 16.54 yuan, down 1.25%, with a rolling PE ratio of 157.24 times, and a total market capitalization of 4.386 billion yuan [1] - The average PE ratio in the medical device industry is 50.97 times, with a median of 36.67 times, placing the company at the 112th position in the industry ranking [1][3] - On June 5, the net outflow of main funds for the company was 19.1 million yuan, although there was an overall inflow of 32.2 million yuan over the past five days [1]

Core Viewpoint - The cell immunotherapy sector has shown significant growth, with a 3.87% increase, ranking second among concept sectors, driven by strong performances from several stocks [1][2]. Group 1: Sector Performance - As of June 3, the cell immunotherapy concept saw 51 stocks rise, with notable gainers including Shutaishen and Guanhao Biological, both reaching a 20% limit up [1]. - Other top performers in the sector included Hainan Haiyao, Rui Zhi Pharmaceutical, and Zuo Li Pharmaceutical, with increases of 9.97%, 13.15%, and 10.66% respectively [1][2]. - Conversely, stocks like Xue Rong Biological, *ST Biological, and Fosun Pharmaceutical experienced declines of 1.76%, 1.14%, and 0.39% respectively [1]. Group 2: Capital Flow - The cell immunotherapy sector attracted a net inflow of 269 million yuan, with 34 stocks receiving significant capital inflows [2]. - Leading the net inflow was Huahai Pharmaceutical, which saw 266 million yuan enter, followed by Guanhao Biological and Hainan Haiyao with inflows of 159 million yuan and 64.85 million yuan respectively [2][3]. - The highest net inflow ratios were recorded for ST Zhongzhu, Hainan Haiyao, and Huahai Pharmaceutical, at 15.16%, 13.79%, and 12.53% respectively [3]. Group 3: Stock Specifics - Huahai Pharmaceutical had a daily increase of 7.63% with a turnover rate of 7.71% and a net capital flow of 266.08 million yuan [3]. - Guanhao Biological surged by 19.97% with a turnover rate of 28.68% and a net capital flow of 159.24 million yuan [3]. - Hainan Haiyao also performed well, increasing by 9.97% with a turnover rate of 6.18% and a net capital flow of 64.85 million yuan [3].

截至6月3日收盘，创新药概念上涨3.38%，位居概念板块涨幅第7，板块内，173股上涨，华纳药厂、舒 泰神、冠昊生物等20%涨停，万邦德、千红制药、昂利康等涨停，诺思兰德、科兴制药、海特生物等涨 幅居前，分别上涨18.82%、14.97%、13.18%。跌幅居前的有*ST苏吴、海创药业、百利天恒等，分别下 跌4.78%、3.73%、2.87%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 中韩自贸区 | 4.23 | 特钢概念 | -0.93 | | 细胞免疫治疗 | 3.87 | 医疗废物处理 | -0.51 | | 重组蛋白 | 3.64 | 果指数 | -0.41 | | 足球概念 | 3.56 | 无线充电 | -0.39 | | 毛发医疗 | 3.51 | 光热发电 | -0.33 | | CRO概念 | 3.41 | 深圳国企改革 | -0.24 | | 创新药 | 3.38 | F5G概念 | -0.23 | | 培育钻石 | 3.11 | 租售同权 | -0.22 | | 仿制药一致性评价 ...

Core Viewpoint - The ophthalmology medical concept sector has shown a significant increase, with a rise of 3.08%, ranking it as the 10th highest among concept sectors, indicating strong market interest and investment potential in this area [1][2]. Group 1: Market Performance - As of June 3, the ophthalmology medical concept sector saw 42 stocks increase in value, with notable performers including Guanhao Biological, which hit a 20% limit up, and ST Zhongzhu, which also reached its limit up [1]. - Other top gainers in the sector included Nuo Si Lan De (up 18.82%), Hai Te Biological (up 13.18%), and Bei Da Pharmaceutical (up 7.34%) [1]. - Conversely, the sector experienced declines from companies such as Kanghong Pharmaceutical (down 2.16%), Chuangwei Digital (down 2.05%), and Jianghe Group (down 1.60%) [1]. Group 2: Capital Flow - The ophthalmology medical concept sector attracted a net inflow of 107 million yuan from major funds, with 25 stocks receiving net inflows, and 12 stocks exceeding 10 million yuan in net inflow [2]. - Guanhao Biological led the sector with a net inflow of 159 million yuan, followed by Bei Da Pharmaceutical (61.32 million yuan), Ma Ying Long (24.37 million yuan), and Hai Te Biological (21.22 million yuan) [2][3]. - The net inflow ratios for ST Zhongzhu, Huashen Technology, and Guanhao Biological were 15.16%, 13.41%, and 11.88%, respectively, indicating strong investor confidence in these stocks [3].

证券代码：300238 证券简称：冠昊生物 公告编号：2025-036 冠昊生物科技股份有限公司 关于股价异动的公告 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动情况 公司股票（证券代码：300238，证券简称：冠昊生物）于 2025 年 5 月 29 日、5 月 30 日、6 月 3 日连续三个交易日收盘价格涨幅偏离值累计达到 30%，根 据深圳证券交易所的相关规定，属于股票交易异常波动的情形。 二、公司关注并核实情况说明 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司目前经营正常，近期公司经营情况及内外部经营环境未发生重大变 化； 3、公司未发现近期公共传媒报道了可能对本公司股票交易价格产生重大影 响的未公开重大信息； 4、公司、控股股东及实际控制人不存在关于公司应披露而未披露的重大事 项，或处于筹划阶段的重大事项； 5、公司控股股东、实际控制人在股票异常波动期间不存在买卖公司股票的 行为。 三、是否存在应披露而未披露信息的说明 公司董事会确认，除在指定媒体已公开披露的信息外，公司目前没有其他任 何根据《深圳证券交易所 ...

Group 1 - The A-share innovative drug sector experienced a significant surge in the afternoon, with notable stocks such as Shutai Shen and Guanhao Bio hitting the 20% daily limit increase [1] - Nuo Si Lan De saw a substantial rise of 18%, while Warner Pharmaceuticals increased by over 17% [1] - Other companies like Ruizhi Medicine and Beilu Pharmaceutical also followed the upward trend [1]

Group 1 - The cell immunotherapy concept index rose by 1.25%, ranking 6th among concept sectors, with 29 stocks increasing in value [1][2] - Notable gainers included Ruizhi Pharmaceutical with a 20% limit up, Hainan Haiyao at limit up, and Shutaishen, Guanhao Biological, and Fosun Pharma with increases of 15.02%, 8.88%, and 5.23% respectively [1][6] - The sector experienced a net outflow of 266 million yuan, with 20 stocks seeing net inflows, and 8 stocks receiving over 10 million yuan in net inflows, led by Hainan Haiyao with a net inflow of 144 million yuan [2][3] Group 2 - Hainan Haiyao, Anke Bio, and Dongcheng Pharmaceutical had the highest net inflow ratios at 35.56%, 5.52%, and 5.27% respectively [3][4] - The top stocks by net inflow included Hainan Haiyao, Fosun Pharma, Ruizhi Pharmaceutical, and Zhaoyan New Drug, with net inflows of 144 million yuan, 54.52 million yuan, 34.78 million yuan, and 31.86 million yuan respectively [2][3] - Stocks with significant declines included Xue Rong Biological, Saifutian, and Jinchang Protein, with decreases of 4.23%, 2.74%, and 2.61% respectively [1][5]